A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Trial to Investigate the Safety and Tolerability of Single and Multiple Oral Doses of DNL747 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
Price : $35 *
At a glance
- Drugs DNL-747 (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Denali Therapeutics Inc
- 19 Nov 2018 Results presented in a Denali Therapeutics media release.
- 11 Nov 2018 New trial record
- 08 Nov 2018 According to a Denali Therapeutics media release, data from this trial will be presented at the Denali 2018 R&D Day on December 10, 2018.